Answers are grounded in this paper and cite their sources.
Field trials evaluated fungicides and bio-agents for controlling leaf spot in niger, indicating effective alternatives are available.
Niger (Guizotia abyssinica L.) is a traditional minor oilseed crop predominantly cultivated in tribal regions of India. Under conducive environmental conditions, niger is susceptible to various diseases, among which leaf spot caused by Alternaria alternata is one of the most predominant, leading to significant yield losses. In recent years, the area under niger cultivation has increased in the Konkan region of Maharashtra; however, there is a limited availability of crop-specific fungicidal recommendations. Additionally, there is a pressing need for effective, eco-friendly disease management alternatives suitable for smallholder farming systems. Therefore, the present investigation was undertaken to evaluate the efficacy of fungicides and bio-agents against leaf spot disease, both under in vitro and field conditions. In the in vitro studies, complete inhibition of Alternaria alternata was observed with treatments of Hexaconazole 5% EC at 0.1%, Carbendazim 12% + Mancozeb 63% WP at 0.2%, and Hexaconazole 4% + Zineb 68% WP at 0.1%. Among the seven bio-agents tested, Pseudomonas fluorescens strain-4 proved to be the most effective, recording the least mycelial growth (22.16 mm) and the highest inhibition (75.36%) of A. alternata. The most promising treatments from the in vitro evaluation were subsequently selected for field trials, integrated with seed treatment. All tested treatments were significantly superior to the untreated control. The lowest disease severity (6.87%) and the highest disease reduction (84.94%) were achieved with seed treatment using Captan 50% WP at 4 g/kg, combined with two foliar sprays of Tebuconazole 50% WG + Trifloxystrobin 25% WG at 0.05%. A comparable level of control was obtained with seed treatment using Captan 50% WP at 4 g/kg, followed by two sprays of Carbendazim 12% + Mancozeb 63% WP at 0.15%, which resulted in 8.70% disease severity and 80.93% disease reduction compared to the control.
No takes yet. Share an insight, caveat, or question.
Wayse et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: